Maertens J, Verhaegen J, Demuynck H, Brock P, Verhoef G, Vandenberghe P, Van Eldere J, Verbist L, Boogaerts M
Department of Haematology, University Hospital Gasthuisberg, Leuven, Belgium.
J Clin Microbiol. 1999 Oct;37(10):3223-8. doi: 10.1128/JCM.37.10.3223-3228.1999.
Efforts to improve the diagnosis of invasive aspergillosis (IA) have been directed towards the detection of fungal antigens, including galactomannan (GM). However, previous evaluations of GM detection have been hampered by a lack of proven cases of IA and by a nonserial study design. This prospective study assessed the diagnostic value of serial screening for circulating GM by using a recently developed sandwich enzyme-linked immunosorbent assay (ELISA) for prolonged-neutropenic and/or steroid-treated patients with hematological disorders. Serum GM levels were monitored twice weekly for 186 consecutive patients at increased risk for IA. The patients were stratified according to the likelihood of IA (proven, probable, possible, and no evidence of IA) by using stringent criteria. Proven IA was defined by characteristic histopathological findings together with a positive culture for Aspergillus species. Autopsy and culture from autopsy specimens was used to verify both positive and negative test results. A total of 2,172 serum samples were tested from 243 episodes (mean, 9 samples/episode). Based on the analysis of 71 patients with confirmed disease status (culture and histology), the sensitivity and specificity of serial GM monitoring were 92.6 and 95.4%, respectively. The positive predictive value was almost 93%, the negative predictive value was 95%, and the efficacy was 94%. False-positive reactions occurred at a rate of nearly 8%, although this figure might have been overestimated. Less than 1% of all tested sera were considered inconclusive. In more than half of the cases, antigenemia was detected before clinical suspicion of IA (median, 6 days before). Serial determination of serum GM by the sandwich ELISA technique is a sensitive tool for the diagnosis of IA in hematological patients at risk. This approach may substantially influence clinical management with regard to preemptive and empirical antifungal therapy.
改善侵袭性曲霉病(IA)诊断的努力一直致力于检测真菌抗原,包括半乳甘露聚糖(GM)。然而,以往对GM检测的评估因缺乏IA确诊病例以及非系列研究设计而受到阻碍。这项前瞻性研究通过使用一种新开发的夹心酶联免疫吸附测定(ELISA),对患有血液系统疾病的长期中性粒细胞减少和/或接受类固醇治疗的患者进行循环GM的系列筛查,评估其诊断价值。对186例IA风险增加的连续患者每周监测两次血清GM水平。根据严格标准,将患者按照IA可能性(确诊、很可能、可能、无IA证据)进行分层。确诊IA定义为具有特征性组织病理学表现且曲霉属培养阳性。尸检及尸检标本培养用于验证检测结果的阳性和阴性。共检测了来自243次病程(平均每次病程9份样本)的2172份血清样本。基于对71例疾病状态确诊(培养和组织学)患者的分析,系列GM监测的敏感性和特异性分别为92.6%和95.4%。阳性预测值近93%,阴性预测值为95%,诊断效能为94%。假阳性反应发生率近8%,尽管该数字可能被高估。所有检测血清中不到1%被认为不确定。在超过半数的病例中,在临床怀疑IA之前(中位数为提前6天)就检测到了抗原血症。通过夹心ELISA技术系列测定血清GM是诊断有风险血液学患者IA的敏感工具。这种方法可能会对抢先和经验性抗真菌治疗的临床管理产生重大影响。